HUTCHMED Withdraws TAZVERIK® in China Following Safety Concerns
Event summary
- HUTCHMED is withdrawing TAZVERIK® (tazemetostat) from China, Hong Kong, and Macau due to safety concerns over secondary hematologic malignancies.
- The withdrawal follows Ipsen's decision to halt the SYMPHONY-1 trial and recall TAZVERIK® in the US.
- All active clinical trials involving tazemetostat in China have been discontinued.
- TAZVERIK® sales in 2025 were US$2.5 million, which is not expected to impact HUTCHMED’s financial guidance.
The big picture
The withdrawal of TAZVERIK® underscores the risks associated with novel oncology therapies, particularly those involving combination treatments. This event highlights the interconnected nature of global regulatory decisions, as Ipsen's actions in the US triggered a cascading effect on HUTCHMED's operations in China. The biopharmaceutical industry continues to grapple with balancing innovation against patient safety, especially in markets with stringent regulatory oversight.
What we're watching
- Regulatory Fallout
- How the China National Medical Products Administration and other regulators respond to the withdrawal and recall.
- Patient Transition
- The impact on existing patients who were treated with TAZVERIK® and their alternative treatment options.
- Pipeline Adjustments
- Whether HUTCHMED can offset the loss of TAZVERIK® revenue with other products in its pipeline.